STAY CONNECTED: Have the stories that matter most delivered every night to your email inbox. Subscribe to our daily local news wrap.
Nanostics Precision Health has created a new tool for screening prostate cancer. (Photo 218515646 © Luchschen | Dreamstime.com)

New blood test unveiled in Alberta for prostate cancer screenings

Sep 29, 2023 | 2:27 PM

EDMONTON, AB – Nanostics Precision Health has created a new tool for screening prostate cancer.

Nanostics’ ClarityDX Prostate test is now available at its newly accredited clinical lab in Edmonton.

The blood test provides crucial support to men between the ages of 40 to 75, and it is able to determine with three times the accuracy of whether a biopsy is necessary following a high-prostate-specific antigen (PSA) test.

Dr. John D. Lewis, CEO of Nanostics and Bird Dogs Chair of Translational Oncology at the University of Alberta said, “This test will reduce the number of unnecessary prostate biopsies, which are invasive, uncomfortable, and carry some risk.”

Research suggests that using ClarityDX Prostate could reduce frivolous prostate biopsies by up to 35 per cent and significantly cut costs.

Globally, the market for the prevention and treatment of prostate cancer surpasses $50 billion annually.

The Alberta Prostate Cancer Research Initiative, along with the University of Alberta, were instrumental in the development and validation of ClarityDX Prostate.

Wendy Beauchesne, CEO of the Alberta Cancer Foundation, said, “We are dedicated to creating more moments for Albertans facing cancer and it’s a misison we share with Dr. Lewis and the Nanostics team.”

Beauchesne said, “Through the launch of ClarityDX Prostate, we are enhancing detection and treatment options. It’s incredible to see what can happen when Albertans come together to support big ideas.”

READ MORE: Lethbridge News Now.

If you have a news tip, question or concern, please email Lethbridge.newsroom@Pattisonmedia.com.